New Mexico Reaches $2.25M Settlement with the Pharmaceutical Company Behind EpiPen Auto-Injectors

New Mexico has reached a $2.25 million settlement with Mylan Inc., the pharmaceutical company behind EpiPen Auto-Injectors, which are used as emergency treatment for severe allergic reactions.

The settlement resolves claims by the New Mexico Department of Justice that Mylan engaged in unfair and anticompetitive practices, including high prices for its EpiPen products, though the company denies any wrongdoing.

Read more at Santa Fe New Mexican